Investment Management Of Virginia Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Investment Management Of Virginia reduced its stake in Abbott Laboratories by 0.45% during the most recent quarter end. The investment management company now holds a total of 112,660 shares of Abbott Laboratories which is valued at $4,616,807 after selling 505 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Abbott Laboratories makes up approximately 1.17% of Investment Management Of Virginia’s portfolio.

Other Hedge Funds, Including , Legacy Private Trust reduced its stake in ABT by selling 400 shares or 7.74% in the most recent quarter. The Hedge Fund company now holds 4,770 shares of ABT which is valued at $196,333. Abbott Laboratories makes up approx 0.03% of Legacy Private Trust’s portfolio.Jacobs Coca reduced its stake in ABT by selling 1,685 shares or 1.73% in the most recent quarter. The Hedge Fund company now holds 95,816 shares of ABT which is valued at $4,167,996. Abbott Laboratories makes up approx 0.93% of Jacobs Coca’s portfolio.

Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.